Mode
Text Size
Log in / Sign up
N/A N=396 Randomized Triple-blind Treatment

A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution

Contact Lens Wear

Enrolled (actual)
396
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: The Primary Safety Endpoint Was Statistical Non-inferiority With Respect to the Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2 at Any Visit Between the Test and Control Solutions. — 2; 4 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Complete MPS (Device); NNR06 (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Bausch & Lomb Incorporated
Primary completion
Oct 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
The Primary Safety Endpoint Was Statistical Non-inferiority With Respect to the Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2 at Any Visit Between the Test and Control Solutions.
2; 4

Summary

The objective of this study is to evaluate the safety and effectiveness of NNR06 Multi-Purpose Solution cleaning and disinfecting solution (Test) compared to COMPLETE Multi-Purpose Solution cleaning and disinfecting solution (Control) when used by habitual contact lens wearers to bilaterally clean and disinfect their contact lenses for approximately three months.

Eligibility Criteria

Inclusion Criteria

  • Is a habitual wearer of one of the following lens types:

Lens Group Lens Material Trade Name Manufacturer

4 Etafilcon A Acuvue2 Vistakon

5-A Balafilcon A PureVision2 Bausch + Lomb

5-C Samfilcon A Ultra Bausch + Lomb

5-Cm Lotrafilcon B Optix Aqua Alcon

5-Cr Senofilcon A Oasys Vistakon

  • Is correctable through spherocylindrical refraction to 32 letters (0.3 logMAR) or better (distance, high contrast) in each eye with soft spherical contact lenses.
  • Has clear central corneas and is free of any anterior segment disorders. 4. Is a habitual user of a lens care product for cleaning, disinfecting, and storage of lenses.
  • Requires lens correction in both eyes. 6. Wears the same manufacturer and brand of lens in both eyes. 7. Agrees to wear study lenses on a daily wear basis for approximately three months.
  • Is willing and able to comply with all treatment and follow-up/study procedures.

Exclusion Criteria

  • Has worn gas permeable (GP) lenses within the last 30 days.
  • 2. Has worn polymethylmethacrylate (PMMA) lenses within the last three months. 3. Has any systemic disease currently affecting ocular health or which in the Investigator's opinion may have an effect on ocular health during the course of the study.
  • Currently wears monovision, multifocal, or toric contact lenses. 5. Has ocular astigmatism of 1.00D or greater in either eye. 6. Is not correctable through spherocylindrical refraction to 32 letters (0.3 logMAR) or better (distance, high contrast) in each eye with soft spherical contact lenses.
  • Has anisometropia (spherical equivalent) of greater than 2.00D 8. Has any grade 2 or greater finding during the slit lamp examination (refer to Appendix B for Methods of Clinical Evaluation).
  • Has corneal infiltrates, of ANY GRADE. 10. Subjects with any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear.
  • Has any scar or neovascularization within the central 4 mm of the cornea. Note that subjects with minor peripheral corneal scarring (that does not extend into the central area), that, in the Investigator's judgment, does not interfere with contact lens wear, are eligible for this study. 12. Is aphakic.
  • Is amblyopic. 14. Has had any corneal surgery (e.g., refractive surgery). 15. Is allergic to any component in the study care products.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02701556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search